In the study, BL-8040 increased the number of tumor-infiltrating CD8+ effector T cells and decreased the number of MDSCs in PDAC tumors, suggesting that CXCR4 inhibition may enhance the therapeutic efficacy of PD-1 blockade in patients with PDAC and warrants confirmation in subsequent randomized trials. This evidence concerns the gene CD8A and neoplasm.